• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Lipid-Modifying Therapies and Stroke Prevention
AbstractPurpose of ReviewWe reviewed lipid-modifying therapies and the risk of stroke and other cerebrovascular outcomes, with a focus on newer therapies.Recent FindingsStatins and ezetimibe reduce ischemic stroke risk without increasing hemorrhagic stroke risk. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors similarly reduce ischemic stroke risk in statin-treated patients with atherosclerosis without increasing hemorrhagic stroke, even with very low achieved low-density lipoprotein cholesterol levels. Icosapent ethyl reduces the risk of total and first ischemic stroke in patients with established cardiova...
Source: Current Neurology and Neuroscience Reports - May 13, 2022 Category: Neuroscience Source Type: research

Current Status of Dyslipidemia Treatment for Stroke Prevention
AbstractPurpose of ReviewElevated cholesterol is an established risk factor for ischemic stroke. The value of statins for stroke prevention has been clear for more than a decade.Recent FindingsHowever, the use of new medication combinations such as ezetimibe or proprotein convertase subtilisin –kexin type 9 inhibitors plus statins is increasing and the value for reducing stroke has been shown for these combination therapies. Recent data also support the strategy of lowering triglycerides for stroke prevention.SummaryA modern approach to dyslipidemia treatment and its relation to stroke prevention is summarized in this paper.
Source: Current Neurology and Neuroscience Reports - June 21, 2020 Category: Neuroscience Source Type: research

Guidelines for Management of Hyperlipidemia: Implications for Treatment of Patients with Stroke Secondary to Atherosclerotic Disease
Abstract After careful review of randomized cardiovascular outcomes trial data, the 2013 ACC/AHA cholesterol guideline focused on using the appropriate intensity of statin therapy to reduce atherosclerotic cardiovascular disease (ASCVD) risk and moved away from recommending specific low-density lipoprotein cholesterol (LDL-C) treatment targets. In patients who have had a stroke or other clinical ASCVD event, a high-intensity statin should be initiated up to age 75 years unless there are safety concerns, including a history of hemorrhagic stroke. A moderate-intensity statin is recommended if there are safety conc...
Source: Current Neurology and Neuroscience Reports - February 2, 2016 Category: Neuroscience Source Type: research